China's Sinopharm has just released its Phase III trial results. It says its vaccine has an antibody rate of 99.5 percent in participants, and the efficacy rate is 79.34 percent. Sinopharm says the results meet the vaccine standards set by the World Health Organization and China's regulators. The company says it has applied to China's drug regulator for approval of the vaccine.